Dongyao Pharmaceutical-B(01875.HK) Leads the Industry in CDMO Technology in the First Half of the Year, Achieving Breakthrough in Global Layout of Core Products.

The information has been released by the Zhitong Finance and Economics APP: Dongyao Pharmaceutical-B (01875.HK) announced its mid-term performance in 2025, with revenues of approximately 489 million yuan and a net profit of about 4.062 million yuan. The net cash flow from operating activities remained positive, reaching 34.83 million yuan in the first half of 2025, a year-on-year increase of 25%.